Supplementary Materials
This PDF file includes:
- Fig. S1. Summary of drug screening results for G3 MB.
- Fig. S2. Multiple kinases that control cell cycle checkpoints were effective against G3 MB.
- Fig. S3. All CHK1/2 inhibitors penetrate MB and behave similarly in multiple models.
- Fig. S4. CHK1/2 inhibition abrogates cell cycle checkpoint signaling in MB cells after treatment with 4-HPC or GEM.
- Fig. S5. LY2606368 abrogates cell cycle arrest after chemotherapy-induced DNA damage in MB cells.
- Fig. S6. Combined CPM and LY2606368 treatment induced apoptosis in additional G3 MB PDX models.
- Fig. S7. LY2606368 and CPM combination therapy delays tumor growth of G3-II and SHHα MB.
- Fig. S8. Summary of mean and median survival of mouse models treated with LY2606368 combination therapy.
- Fig. S9. No evidence of intrinsic drug resistance after combination therapy with CPM and LY2606368.
- Fig. S10. Bioluminescence and immunohistochemistry data from G3-II models treated with LY2606368 and CDDP.
- Fig. S11. Combination therapy using GEM and LY2606368 is effective in other models of G3 MB and increases DNA damage and apoptosis in vivo.
- Fig. S12. Combination therapy using GEM and LY2606368 increases DNA damage in SHH MB in vivo.
- Table S1. Summary of in vitro drug sensitivity data.
- Table S2. Summary of different MB models used and the location of experiments performed.
